ClinicalTrials.gg
Not yet recruitingNCT07217990NoCUT-BCUpdated Nov 9, 2026

Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer

A Phase 1/2 interventional study of Neoadjuvant Chemotherapy and Radiation Therapy in Breast Cancer, HER2-positive Breast Cancer and Triple Negative Breast Cancer, sponsored by Ohio State University Comprehensive Cancer Center. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Primary conditionTriple Negative Breast NeoplasmsRegistry: Breast NeoplasmsReclassifiedWhy we changed it
Registry
Breast Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Triple Negative Breast Neoplasms
Why
  1. The study's listed conditions name Triple Negative Breast Neoplasms, a narrower term within Breast Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Ohio State University Comprehensive Cancer Center · Phase 1/2, Interventional, and Treatment

How we know

Updated Nov 9, 2026Start date movedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
84
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 645 studies in Triple Negative Breast Neoplasms with a site in United States — 159 open to participants now, 263 under way, 16 of them phase 3. Triple Negative Breast Neoplasms · United States.

Planned enrollment
232nd of 605
84 · median 52
Started
2027
with 3 others
Phase 1/2
107 of 645
30 open now
Primary completion
2028-01
later than 166 of 262 live
Registered
610th of 645
by date

Among the 645 studies in Triple Negative Breast Neoplasms with a site in United States, this one is the 232nd largest by planned enrollment of the 605 interventional ones that give a count, is one of 4 that started in 2027, is one of 107 in phase 1/2, reaches primary completion later than 166 of the 262 other live ones, and was the 610th registered.

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 441 are open to participants now.

Browse Triple Negative Breast Neoplasms studies →

Open to participants now

159 of the 645 studies in Triple Negative Breast Neoplasms with a site in United States are open now. Recruiting first, the newest first:

154 more — sign in →

All 159 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 329 Triple Negative Breast Neoplasms studies recruiting now, 229 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 645 studies in Triple Negative Breast Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This study will evaluate the efficacy and non-inferiority of a non-surgical approach for the treatment of patients with locally advanced breast cancer.

Read the detailed description

Primary Objective: To determine if a non-surgical approach to breast cancer patients with an exceptional response to NAC leads to similar recurrence rates compared to standard of care (SOC).

Exploratory Objectives

  1. To study personalized predictive biomarkers of response to chemotherapy and predictors of residual disease from tumor samples and circulating biomarkers.
  2. To validate our internally developed deep learning model to predict pathological complete response (pCR) postNAC in breast cancer patients.

Outline: This is a phase II trial that will accrue up to 84 participants. Patients will receive standard of care (SOC) neoadjuvant chemotherapy and will be evaluated for enhanced clinical complete response (ecCR) after treatment. The ecCR will be evaluated using a trimodal approach, which includes the use to Magnetic Resonance Imaging (MRI), image-guided biopsy, and circulating tumor DNA (ctDNA) analysis. Participants who achieve an ecCR will be placed in the non-surgical arm (Arm A), while those who do not achieve an ecCR will be placed in the surgical arm (Arm B).

03

Conditions studied

  • Breast Cancer
  • HER2-positive Breast Cancer
  • Triple Negative Breast Cancer

Browse trials for

04

In context

Triple Negative Breast Neoplasms Reclassified

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 441 are open to participants now.

This study's planned enrollment of 84 is above the median of 60 across 1,053 interventional studies indexed under Triple Negative Breast Neoplasms.

Browse Triple Negative Breast Neoplasms studies →

Lead sponsor

Ohio State University Comprehensive Cancer Center is the lead sponsor of 376 studies on the registry; 82 are open to participants now.

Of its 38 completed or terminated interventional studies of FDA-regulated products, 19 (50%) have results posted.

Compared within Triple Negative Breast Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Breast Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

The criteria were revised on the registry on Nov 9, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of signed and dated form
  2. Stated willingness to comply with all study procedures and availability for the duration of the study
  3. Male or female, aged 18 years or older
  4. Early-stage breast cancer diagnosis (cT1-3 N0 or cT1-2 N1) and a Human Epidermal Receptor 2 ()-positive or triple negative breast cancer (TNBC) tumor molecular subtype
  5. Cannot have extensive calcifications in the breast (for complex cases, a patient with calcification's eligibility will be discussed by the study co-principal investigators (PIs) and the treating physicians)
  6. Planning to receive chemotherapy (NAC) and radiation therapy (RT)

Exclusion criteria

Exclusion Criteria:

  1. Pregnancy or lactation
  2. Inmate or prisoner
  3. Treatment with an drug or other intervention throughout their breast cancer treatment
  4. Patients with skin involvement and/or distant
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

06

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
84 participants (estimated)

Study arms

  • Experimental
    Arm A (eeCR, non-surgical)

    Patients will receive standard of care (SOC) neoadjuvant chemotherapy and will be evaluated for enhanced clinical complete response (ecCR) after treatment. Participants who achieve an ecCR will be placed in the non-surgical arm. Participants will receive radiation therapy and routine and additional screening MRIs during follow up.

    Drug: Neoadjuvant Chemotherapy · Radiation: Radiation Therapy · Procedure: MRI · Procedure: Biopsy · Procedure: Biospecimen collection

  • Experimental
    Arm B (non-eeCR, surgical)

    Patients will receive standard of care (SOC) neoadjuvant chemotherapy and will be evaluated for enhanced clinical complete response (ecCR) after treatment. Participants who do not achieve an ecCR will be placed in the surgical arm. Participants will undergo a lumpectomy or mastectomy, receive radiation therapy, and routine follow-up.

    Drug: Neoadjuvant Chemotherapy · Radiation: Radiation Therapy · Procedure: MRI · Procedure: Breast Cancer Surgery · Procedure: Biopsy · Procedure: Biospecimen collection

Interventions

  • DrugNeoadjuvant Chemotherapy

    Participants will receive standard of care neoadjuvant chemotherapy

  • RadiationRadiation Therapy

    Radiotherapy simulation parameters will be at the discretion of the treating physician to account for the patient's body habitus, tumor bed location, and tolerability of the prone or supine positions, however, the recommended approach will be whole-breast RT (WBRT) in the prone position, for cT1-3 N0 patients who achieve ecCR. For cT1-2 N1 patients who achieve ecCR WBRT with nodal inclusion and lymph node boost will be performed in the supine position.

    Also known as: Radiotherapy

  • ProcedureMRI

    Participants will undergo MRI

    Also known as: Magnetic Resonance Imaging

  • ProcedureBreast Cancer Surgery

    Participants will undergo surgery to treat their breast cancer. Either a lumpectomy or a mastectomy will be performed.

    Also known as: Lumpectomy, Mastectomy

  • ProcedureBiopsy

    Participants undergo biopsy

  • ProcedureBiospecimen collection

    Participants undergo blood and plasma collection

07

What researchers measure

Primary outcomes

  1. Disease-Free Rate

    The study endpoints of disease-free rate and locoregional control will be determined in patient follow up by utilizing MRIs, annual mammograms and clinical assessments in conjunction with ctDNA status.

    Time frame: At 12 months

Secondary outcomes

  1. Locoregional control

    The study endpoints of disease-free rate and locoregional control will be determined in patient follow up by utilizing MRIs, annual mammograms and clinical assessments in conjunction with ctDNA status.

    Time frame: At 2, 3 and 5 years

  2. Disease-free survival

    Survival analysis will be conducted for time to event data, and the disease control or survival rate at specific times will be estimated based on the survival analysis along with the 95% CI.

    Time frame: Up to 5 years

  3. Treatment related adverse events

    Toxicities will be recorded using CTCAE v5.0

    Time frame: Up to 5 years

08

Study locations

1 site
09

References and documents

Related links

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Jan 2028, 12 months later.

Of 118 phase 1/2 interventional studies under Triple Negative Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 79. This study's planned 12 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: start Sep 2026 → Jan 2027, primary completion Dec 2027 → Jan 2028 and completion Dec 2027 → Jan 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2025
First posted
Oct 20, 2025
StartEst.
Jan 15, 2027was Sep 2026
Primary completionEst.
Jan 31, 2028was Dec 2027
CompletionEst.
Jan 31, 2028was Dec 2027
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 15, 2026→Jan 15, 2027
Nov 9, 2026
Primary completion
Dec 31, 2027→Jan 31, 2028
Nov 9, 2026
Study completion
Dec 31, 2027→Jan 31, 2028
Nov 9, 2026
Eligibility
1 inclusion criterion added
What changed in the criteria
Inclusion criteria
  • AddedCannot have extensive calcifications in the breast (for complex cases, a patient with calcification's eligibility will be discussed by the study co-principal investigators (PIs) and the treating physicians)
Nov 9, 2026
Sponsor
Collaborators added: Natera, Inc.
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Start date Sep 15, 2026→Jan 15, 2027
    Primary completion Dec 31, 2027→Jan 31, 2028
    Study completion Dec 31, 2027→Jan 31, 2028
    Eligibility 1 inclusion criterion added
    What changed in the criteria
    Inclusion criteria
    • AddedCannot have extensive calcifications in the breast (for complex cases, a patient with calcification's eligibility will be discussed by the study co-principal investigators (PIs) and the treating physicians)
    Sponsor Collaborators added: Natera, Inc.
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07217990
Collaborators
Gateway for Cancer Research, Natera, Inc.
Responsible party
Sachin Jhawar (Principal Investigator, Ohio State University Comprehensive Cancer Center) — Principal investigator
First posted
Oct 20, 2025
Start date
Jan 15, 2027 (estimated)
Primary completion
Jan 31, 2028 (estimated)
Completion
Jan 31, 2028 (estimated)
Last update
Nov 9, 2026

Study contacts

The Ohio State University Comprehensive Cancer Center
Contact
OSUCCCClinicaltrials@osumc.edu
800-293-5066
Sachin Jhawar, MD
principal investigator · Ohio State University Comprehensive Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion